美国代谢与减重手术学会2016年最新立场声明解读

发布时间：2018-03-10 10:24

本文选题：肥胖症　切入点：代谢和减重手术　出处：《中国实用外科杂志》2017年01期 　论文类型：期刊论文

【摘要】：2016年4月,美国代谢与减重手术学会就代谢与减重手术的长期生存获益、胃内球囊和迷走神经阻断治疗病态肥胖症等阐述最新原则立场。该系列声明认为,越来越多的临床证据表明减重和代谢手术是病态肥胖症最有效的治疗手段,并着重强调了长期的减重和生存获益是手术区别于非手术治疗手段的主要优势;根据美国胃肠道和内镜外科医师协会提供的资料,胃内球囊可以有效、安全地治疗肥胖症;基于目前的短期证据,作为一种新型减重装置,迷走神经阻断装置适用于BMI为35~45的病人,但其减重效果的长期有效性和病人耐受性仍有待继续观察。
[Abstract]:In April 2016, the American Society of metabolic and bariatric surgery for metabolic and bariatric surgery long-term survival benefit, intragastric balloon and vagotomy for morbid obesity such as the latest stance. This series of statements that, more and more clinical evidences show that bariatric and metabolic surgery is the most effective treatment for morbid obesity, and emphasizes the importance of long-term weight loss and survival benefit is the main advantage of operation is different from the non operative treatment methods; according to the gastrointestinal and endoscopic surgeons Association, the intragastric balloon can effectively and safely treat obesity; short term based on the current evidence, as a new type of weight reducing device, the vagus nerve blocking device is suitable for BMI 35~45 patients but the weight loss effect, long-term efficacy and patient tolerance still need to continue to observe.

【作者单位】：第二军医大学附属长海医院普外科;
【分类号】：R6

【相似文献】